Clinical Trials for Fusion Pharmaceuticals Inc.

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Fusion Pharmaceuticals Inc.

Clinical Trials (5)

NCT06909825
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PHASE2Active, not recruiting
85 participants
Started: Feb 26, 2025 · Completed: Aug 12, 2030
1 condition1 sponsor4 locations
NCT06147037
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
PHASE1Recruiting
169 participants
Started: Jul 31, 2024 · Completed: Dec 30, 2027
7 conditions2 sponsors15 locations
NCT06402331
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PHASE2Recruiting
100 participants
Started: Mar 5, 2024 · Completed: Jan 23, 2031
1 condition1 sponsor18 locations
NCT05219500
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
PHASE2Active, not recruiting
115 participants
Started: Dec 16, 2021 · Completed: Jul 31, 2026
1 condition1 sponsor2 locations
NCT03746431
A Phase 1 Study of [225Ac]-FPI-1434 Injection
PHASE1/PHASE2Recruiting
253 participants
Started: Jan 17, 2019 · Completed: Jun 30, 2026
10 conditions1 sponsor13 locations